CA-CROWN-BIOSCIENCE
9.3.2023 14:31:40 CET | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the opening of a new site in Singapore to expand the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
The new facility will initially offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models, alongside supporting analytical biomarker capabilities including flow cytometry and pathology services. The Company is also collaborating with the established biomedical community in Singapore to bring not only the foundational capabilities of Crown Bioscience’s preclinical services to Singapore but also novel technologies and services.
To support the growth goals for the Singapore site, and with a particular focus on the burgeoning local biotech industry, Crown Bioscience is pleased to announce it has entered into a distribution agreement with Biosys Corporation Pte Ltd., a specialized commercial partner with unique contacts within the Singaporean life sciences ecosystem.
Commenting on the opening of the new laboratory, Keefe Chng, PhD, executive director, and general manager of the Singapore facility, commented; “We are extremely excited to join the local biomedical community. Our core capabilities and experience will help the booming local biotech industry advance their preclinical and translational studies, while at the same time enable Crown Bioscience to bring unique high-end technologies to our global partners.”
Mr Ivan Fu, Director of Biosys Corporation, added: “We believe that Crown Bioscience’s new facility in Singapore will inject a new standard for quality and innovation in the local preclinical market. As a distributor of Crown Bioscience in Singapore, our aim is to accelerate our customers research to improve the future of cancer treatment.”
The investment in Singapore reflects a broader strategy to increase Crown Bioscience’s ability to support APAC-based clients with a local presence. In 2022 the Company announced a joint venture launch with sister company MBL in Japan, alongside facility expansions and upgrades to the Company’s Chinese presence. These investments coincide with the fast-growing biotechnology sector across the region, while recognizing the importance of local understanding and language in support of the company’s client base.
To mark the official site opening, a ribbon cutting event was held in February with executives from Crown Bioscience and Biosys Corporation in attendance.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their R&D in oncology, immuno-oncology, and immune-mediated inflammatory diseases. Crown Bioscience is the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. We have developed the largest commercially available PDX collection. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 12 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005059/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Radial Selects Riskified to Power Payment Fraud and Refund/Return Protection for Merchant Client Portfolio9.3.2026 15:00:00 CET | Press release
The partnership brings Riskified’s AI-powered platform for payment fraud, refund claim, and return abuse protection to Radial’s global network of merchants Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced a strategic partnership with Radial, a leading 3PL set to become Paxon later this year. Radial will integrate with Riskified’s AI-powered platform to help its merchants approve more legitimate orders and reduce losses from payment fraud, including many merchants that use Shopify as their ecommerce platform. Radial supports many of the world’s most recognized retail brands with a global ecommerce fulfillment network of more than 20 centers across North America, helping merchants deliver orders quickly and cost effectively. By bringing Riskified’s AI-powered fraud decisioning into its commerce ecosystem, Radial gives merchants the surgical ability to calibrate the checkout experience according to risk—without slowing fulfillment. This also suppo
Boomi Activates Data for the Enterprise9.3.2026 14:00:00 CET | Press release
New platform innovations activate contextual data to power production-scale enterprise AI, with a new European platform instance for localized control Boomi™, the data activation company, today announced new capabilities within the Boomi Enterprise Platform. Data activation brings data to life across systems and processes, delivering it with the right context and timing to power everything from AI to BI. The Boomi Enterprise Platform, the foundation that puts data in motion, now adds new semantic context to help AI agents operate on grounded business realities, expands governed SAP data movement with change data capture, enhances transparency and oversight across agentic workflows, and introduces a dedicated European platform instance for localized data control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309682526/en/ Boomi Activates Data for the Enterprise “Last year, Boomi helped enterprises move from experimentatio
Thredd Accelerates in 2026 with its Global Platform and Delivering Enterprise-Scale Outcomes9.3.2026 14:00:00 CET | Press release
Thredd, the AI-first issuer processing platform, today announced a major acceleration phase for 2026, marked by the appointment of Marilyn McDonald as Chief Technology Officer and the promotion of Ryan Dew to Chief Product Officer. Thredd has never been in a stronger position. A fully cloud-native version of its global platform is live in the United States, with end-to-end credit capabilities launching in the coming months alongside a state-of-the-art debit platform and modern unified ledger. Marilyn McDonald joins as CTO to lead the next phase of enterprise-scale execution. She succeeds Edwin Poot, who helped lead the modernisation of Thredd’s architecture and technology stack, laying the foundation for cloud-native and agentic growth. Marilyn brings global transformation experience from senior roles at Citigroup, Mastercard, Expedia Group and StubHub. Her focus is on strengthening operational readiness, bank-grade delivery, enterprise execution and continuous resilience as Thredd sca
MariaDB to Acquire GridGain: Architecting the Real-Time Foundation for the Agentic Enterprise9.3.2026 14:00:00 CET | Press release
Strategic acquisition unites MariaDB’s mission-critical relational database with GridGain’s extreme in-memory speed to power the next generation of AI applications MariaDB plc today announced that it has entered into a definitive agreement to acquire GridGain Systems, Inc., the pioneer of in-memory computing and creator of open source Apache Ignite. By merging MariaDB’s AI-ready relational database with GridGain’s scalable, in-memory power, MariaDB is setting a new industry standard: sub-millisecond data infrastructure for the agentic era. Closing the AI Latency Gap As enterprises move beyond passive chatbots toward agentic AI – autonomous systems that reason, plan and execute tasks – they are quickly becoming limited by traditional data architectures. AI agents require real-time access to massive datasets with zero friction. This acquisition bridges that gap by fusing: MariaDB’s reliability: Proven, ACID-compliant transactional integrity for the world’s most sensitive data, with nativ
Safe Software Announces the Peak of Data and AI 2027, a Premier Global Conference, in London, UK9.3.2026 14:00:00 CET | Press release
Safe Software (Safe) officially announced today the return of its global user conference, the Peak of Data and AI, taking place March 9–11, 2027, at the QEII Centre in London, UK. A Partner Summit will kick off the event on March 8, 2027, bringing together Safe’s global partner community ahead of the main conference. Hosted every two years, the Peak of Data and AI has evolved from Safe Software’s long-running user conference into a premier global event for data and AI professionals. The conference alternates between North America and international locations, with previous events held in Bonn, Germany (2023) and Seattle, Washington (2025). “At the Peak of Data and AI, we bring together the people who are shaping how organizations use data to drive real-world outcomes,” said Don Murray, CEO of Safe Software. “With London as our host city in 2027, we’re excited to connect with the global community to learn, listen, and share what’s next for data and AI.” The three-day conference will feat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom